Why the study?
What are the pharmacokinetic differences in the metabolism of procainamide between normal subjects and patients with heart disease?
What are the pharmacokinetic differences in the metabolism of procainamide between normal subjects and patients with heart disease?
Patients with heart disease exhibit delayed elimination and higher peak plasma concentrations of procainamide and its active metabolite NAPA compared to healthy subjects, suggesting a need for dose adjustments.
Answers are grounded in this paper and cite their sources.
May warrant procainamide dose caution in cardiac patients; extends healthy-volunteer PK data but leaves open prospective validation.
N‐Acetylprocainamide (NAPA) has been well documented as a metabolite of pro cain amide (PA) in man. The objective of the present study was to separate and quantify PA and its metabolites in man. Ten subjects (5 normal and 5 patients with heart disease) were given 40 µCi of PA− 14 C orally, and samples of blood, urine, and expired air were collected for 72 hr. Each subject received 500 to 1,000 mg of PA (7 to 13 mg/kg). During the 72 hr after dosing, 73% to 91% of the dose was excreted in urine. During the first 24 hr, 31% to 56% of the dose [48 ± 2.2 (mean ± SEM)] was PA; 7% to 24% (15 ± 1.8) of the dose was NAPA; 6% to 10% (7 ± 0.5) of the dose was an unknown metabolite (R f = 0.0); and 2% to 4% (3 ± 0.2) of the dose was another unknown metabolite (R f = 0.3). No radioactivity was detected in expired air. Less than 0.2% of the dose was accounted for as either p‐aminobenzoic acid or as p‐acetamidobenzoic acid. The maximum concentration of PA in plasma for all 10 subjects was 5.6 ± 0.9 µg/ml, 4.2 ± 0.3 µg/ml for the normal subjects and 7.1 ± 1.4 µg/ml for the patients. The T½ for the elimination of PA was 2.9 ± 0.5 hr for the normals and 5.5 ± 0.9 hr for patients. The maximum concentration of NAPA in plasma for all subjects was 2.8 ± 0.6 µg/ml, 1.6 ± 0.3 µg/ml for normal subjects and 4.1 ± 0.8 µg/ml for patients. In 2 patients, concentrations of NAPA (4.0 and 5.6 µg/ml) were as high or higher than those of PA.
No takes yet. Share an insight, caveat, or question.
Giardina et al. (1976) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: